News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
811,389 Results
Type
Article (74151)
Company Profile (644)
Press Release (736594)
Section
Business (227361)
Career Advice (3718)
Deals (39299)
Drug Delivery (127)
Drug Development (89264)
Employer Resources (195)
FDA (17815)
Job Trends (17108)
News (387521)
Policy (38718)
Tag
Academia (2980)
Alliances (55887)
Alzheimer's disease (1428)
Approvals (17769)
Artificial intelligence (247)
Bankruptcy (398)
Best Places to Work (12633)
Biotechnology (440)
Breast cancer (248)
Cancer (1898)
Cardiovascular disease (153)
Career advice (3161)
CAR-T (146)
Cell therapy (415)
Clinical research (71515)
Collaboration (747)
Compensation (389)
COVID-19 (2843)
C-suite (186)
Data (1720)
Diabetes (241)
Diagnostics (6841)
Earnings (92855)
Employer resources (166)
Events (127450)
Executive appointments (622)
FDA (18807)
Funding (662)
Gene therapy (293)
GLP-1 (785)
Government (5043)
Healthcare (20832)
Infectious disease (2971)
Inflammatory bowel disease (139)
Interviews (726)
IPO (17700)
Job creations (4988)
Job search strategy (2593)
Layoffs (522)
Legal (9892)
Lung cancer (279)
Manufacturing (273)
Medical device (14510)
Medtech (14515)
Mergers & acquisitions (21976)
Metabolic disorders (651)
Neuroscience (1900)
NextGen: Class of 2025 (7630)
Non-profit (5075)
Northern California (2221)
Obesity (360)
Opinion (264)
Patents (186)
People (63638)
Phase I (22095)
Phase II (31200)
Phase III (23505)
Pipeline (801)
Postmarket research (3257)
Preclinical (9686)
Radiopharmaceuticals (264)
Rare diseases (369)
Real estate (7144)
Regulatory (25737)
Research institute (2649)
Resumes & cover letters (579)
Southern California (1924)
Startups (4192)
United States (20404)
Vaccines (728)
Weight loss (273)
Date
Today (186)
Last 7 days (859)
Last 30 days (3122)
Last 365 days (37122)
2025 (5649)
2024 (37897)
2023 (42567)
2022 (53926)
2021 (58723)
2020 (57663)
2019 (51302)
2018 (39084)
2017 (36837)
2016 (37746)
2015 (43738)
2014 (38423)
2013 (34408)
2012 (36309)
2011 (36431)
2010 (35861)
Location
Africa (1190)
Arizona (227)
Asia (48477)
Australia (8316)
California (5197)
Canada (1782)
China (435)
Colorado (239)
Connecticut (258)
Europe (109074)
Florida (750)
Georgia (183)
Illinois (532)
Indiana (289)
Maryland (825)
Massachusetts (4069)
Michigan (224)
Minnesota (369)
New Jersey (1468)
New York (1475)
North Carolina (998)
Northern California (2221)
Ohio (187)
Pennsylvania (1163)
South America (1563)
Southern California (1924)
Texas (766)
Utah (161)
Washington State (517)
811,389 Results for "chugai pharmaceutical co ltd japan".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technology
January 8, 2025
·
2 min read
Press Releases
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
December 13, 2024
·
11 min read
Press Releases
Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
December 3, 2024
·
4 min read
Drug Development
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
Verrica Pharmaceuticals Inc. announced that its development and commercialization partner, Torii Pharmaceutical Co., Ltd., reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of Molluscum Contagiosum in Japan.
December 15, 2023
·
4 min read
Press Releases
Meiji Seika Pharma: Announcement of the Establishment of Local Subsidiary “Taiwan Meiji Pharma Co., Ltd.” in Taiwan
December 25, 2024
·
1 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
Press Releases
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
February 20, 2025
·
13 min read
Business
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) and Sato Pharmaceutical Co., Ltd., a leading pharmaceutical company, today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Japan.
February 28, 2024
·
6 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
1 of 81,139
Next
